Cara Therapeutics Capital Markets Day

Mr. Posner has served as Cara’s President and Chief Executive Officer since November 2021 and has served as a member of Cara’s board since August 2018. Mr. Posner has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz® and Enbrel®. Since July 2017, he has been the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University.

Dr. Goncalves brings more than 17 years of leadership experience in the biopharmaceutical industry to Cara. Most recently, she served as Vice President, Medical Affairs for Dermatology and Neurology at Celgene Corporation where she was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA® for psoriasis. Previously, Dr. Goncalves held the position of Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S. subsidiary of LEO Pharma A/S. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas. Dr. Goncalves received her M.D. from the University of Cape Town, South Africa.

Mr. Vandal has served as our Sr. Vice President of Commercial since June 2014. He has more than 25 years of executive and commercial leadership experience in the pharmaceutical industry. Prior to joining Cara Therapeutics, Eric was the Vice President, Sales and Marketing for Nuvo Research Inc, a specialty pharmaceutical company specializing in topical pain products. At Nuvo Research, Eric built and lead a commercial team of 25 employees in re-launching SYNERA® Patch into the interventional pain physician segment as well as pioneering its efforts to establish SYNERA® Patch in large corporate health care companies. Prior to joining Nuvo Research, Eric was Senior Director, Marketing for King Pharmaceuticals where he led the company’s hospital business unit. At King Pharmaceuticals, he oversaw the company’s hospital franchises, including their hemostasis portfolio (Thrombin-JMI®) and launched their pain franchise into the hospital segment. Prior to working at King Pharmaceuticals, Eric was at Alpharma Pharmaceuticals where he was Senior Director, Marketing as well as the Regional Business Director for the Northeast Region. At Alpharma, he was the head of the marketing department that successfully launched the first topical NSAID in the United States, FLECTOR® Patch, and significantly grew the KADIAN® Capsule business. Eric previously worked for Endo Pharmaceuticals where he took on roles of increasing responsibility within its commercial organization, including leadership over the launch of PERCOCET® line extensions, OPANA® and OPANA® ER franchise as well as FROVA® Tablets. Eric began his career working in a variety of sales and marketing roles for Schering-Plough and SmithKline Beecham. Eric holds a B.A. in Economics from Harvard University.

Dr. Topf is currently an Assistant Clinical Professor of Medicine at Oakland University William Beaumont School of Medicine, and he teaches residents and fellows at St. John Hospital and Medical Center in Detroit. Since 2008 he has written a nephrology blog focused on teaching clinical nephrology at www.pbfluids.com. He is also the co-creator of NephMadness and NephJC.

Dr. Scherer is an Assistant Professor at the NYU Grossman School of Medicine in both the Divisions of Palliative Care and the Division of Nephrology. Dr. Scherer leads the Kidney CARES (Comprehensive Advanced Renal Disease and End Stage Renal Disease Support) Program at NYU Langone Health. She is a recipient of a palliative care leadership award through the Cambia Health Foundation Sojourn’s Scholar Leadership Program. Dr. Scherer has served on the Public Policy Committee for the American Society of Nephrology as well as for the American Academy of Hospice and Palliative Medicine.

Dr. Chovatiya is Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine. Dr. Chovatiya directs the Center for Eczema and Itch at Northwestern, and his clinical focus includes atopic dermatitis, eczema, chronic itch, and other chronic inflammatory skin disorders including seborrheic dermatitis, psoriasis, urticaria, hidradenitis, and vitiligo.